Related Experiment Video
Updated: Jun 28, 2025

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
Published on: April 28, 2023
Putting More Weight on Obesity Trials in Heart Failure
Josephine Harrington1,2, Naveed Sattar3, G Michael Felker4,5
1Division of Cardiology, Department of Internal Medicine, Duke University Medical Center, Durham, NC, USA. josephine.harrington@duke.edu.
Purpose Of Review:
To review ongoing and planned clinical trials of weight loss among individuals with or at high risk of heart failure.
Recent Findings:
Intentional weight loss via semaglutide among persons with heart failure and preserved ejection fraction and obesity significantly improves weight loss and health status as assessed by the KCCQ-CSS score and is associated with improvements in 6-min walk test. Ongoing and planned trials will explore the role of intentional weight loss with treatments such as semaglutide or tirzepatide for individuals with heart failure across the entire ejection fraction spectrum.
Related Concept Videos
Heart Failure Drugs: β-Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Diuretics
Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Pathophysiology of Heart Failure
Clinical Trials
There are four phases in a clinical trial. A phase one...

